A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors (NCT07213609)
A Phase 1/2 Open-label, Multicenter Study of Oral GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK5460025 alone or in combination (potential combinations may be included in future amendments to the protocol) with other anti-cancer agents can decrease tumor size, is safe, well-tolerated, and how the drug is processed in the body over time.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Aurora, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (22 Sites)
- GSK Investigational Site — Aurora, Colorado
- GSK Investigational Site — Detroit, Michigan
- GSK Investigational Site — Canton, Ohio
- GSK Investigational Site — Nashville, Tennessee
- GSK Investigational Site — Hamilton, Ontario
- GSK Investigational Site — Toronto, Ontario
- GSK Investigational Site — Montreal, Quebec
- GSK Investigational Site — Copenhagen,
- GSK Investigational Site — Chiba,
- GSK Investigational Site — Osaka,
- GSK Investigational Site — Tokyo,
- GSK Investigational Site — Tokyo,
- GSK Investigational Site — Amsterdam,
- GSK Investigational Site — Utrecht,
- GSK Investigational Site — Barcelona,
- GSK Investigational Site — Madrid,
- GSK Investigational Site — Madrid,
- GSK Investigational Site — Madrid,
- GSK Investigational Site — Madrid,
- GSK Investigational Site — Lund,
- GSK Investigational Site — Stockholm,
- GSK Investigational Site — Uppsala,
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neoplasms, Colorectal
Explore by condition: All Neoplasms, Colorectal clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.